For the quarter ending 2025-09-30, RLMD had $31,133 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Unrealized (gain) on short-term investments | - | 141,934 |
| Net loss | -10,091,496 | -27,425,907 |
| Stock-based compensation | 3,607,554 | 7,926,448 |
| Realized gain on short-term investments | -81,439 | 110,156 |
| Unrealized gain on short-term investments | 212,210 | - |
| Fair value changes on stock appreciation rights | 216,640 | - |
| Prepaid expenses and other assets | 493,119 | -411,834 |
| Accounts payable | 91,191 | -2,768,652 |
| Stock appreciation rights compensation | - | 27,649 |
| Accrued expenses | -36,140 | -2,388,191 |
| Net cash used in operating activities | -6,721,856 | -24,468,909 |
| Purchase of short-term investments | 233,932 | 809,375 |
| Sale of short-term investments | 6,986,921 | 22,847,630 |
| Net cash provided by investing activities | 6,752,989 | 22,038,255 |
| Proceeds from options exercised for common stock | - | 0 |
| Atm expenses | 0 | 73,021 |
| Net cash (used in)/provided by financing activities | 0 | -73,021 |
| Net decrease in cash and cash equivalents | 31,133 | -2,503,675 |
| Cash and cash equivalents at beginning of period | 3,857,026 | - |
| Cash and cash equivalents at end of period | 1,384,484 | - |
RELMADA THERAPEUTICS, INC. (RLMD)
RELMADA THERAPEUTICS, INC. (RLMD)